Pharmaceutical News

RSS

Takeda submits NDA to FDA for fixed-dose combination of azilsartan medoxomil plus CLD to treat hypertension

Takeda Pharmaceutical Company Limited announced today that Takeda Global Research & Development Center, Inc. U.S., submitted a New Drug Application to the U.S. Food and Drug Administration for an investigational fixed-dose combination of azilsartan medoxomil plus chlorthalidone for the treatment of hypertension, or high blood pressure.

24 Feb 2011

G-CSF treatment improves inadequate endometrium during IVF cycles

During in vitro fertilization cycles, treatment with a medication called granulocyte-colony stimulating factor significantly improves inadequate endometrium, according to a report published electronically on February 15 in Fertility and Sterility - the official journal of the American Society for Reproductive Medicine.

24 Feb 2011

New strategies to improve developing countries' access to low-cost generic drugs needed, experts say

New strategies that ensure developing countries have access to low-cost generic medicines and encourage innovation are needed, according to experts who attended a recent meeting sponsored by the WHO, World Intellectual Property Organization, and World Trade Organization (WTO) that addressed growing concern that strict intellectual property protections are limiting access to low-cost generic medicines, BMJ News reports.

24 Feb 2011

UBC study shows Canadians and Americans receive different drug information online

Americans and Canadians are getting vastly different search results when they look up prescription drug information online, says a study by researchers at the University of British Columbia.

24 Feb 2011

Scientists find bovine colostrum can massively reduce leaky gut syndrome

Scientists investigating natural ways to enhance athletic performance have found that bovine colostrum can massively reduce gut permeability - otherwise known as 'leaky gut syndrome.'

24 Feb 2011

Aminothiazoles as therapeutic leads for prion diseases

Scientists who examined more than 10,000 chemical compounds during the last year in search of potential new drugs for a group of untreatable brain diseases, are reporting that one substance shows unusual promise.

24 Feb 2011

New vaccine offers hope against Hepatitis C

Immunology: Three percent of the world's population is currently infected by hepatitis C. The virus hides in the liver and can cause cirrhosis and liver cancer, and it's the most frequent cause of liver transplants in Denmark.

24 Feb 2011

FDA approves ONGLYZA to treat type 2 diabetes patients with renal impairment

Bristol-Myers Squibb Company and AstraZeneca today announced that the U.S. Food and Drug Administration has approved the inclusion of data from two clinical studies in an update to the ONGLYZA U.S. Prescribing Information for adult type 2 diabetes patients.

24 Feb 2011

CST, Astellas Pharma enter commercialization partnership for cancer diagnostic, therapeutic products

Cell Signaling Technology, Inc. of Danvers, MA announced today a joint commercialization partnership with Astellas Pharma, Inc. of Tokyo, Japan focused on the delivery of personalized cancer therapeutics and diagnostics.

From Cell Signaling Technology 24 Feb 2011

Polio: Myanmar plans vaccination campaign after confirming first new case in three years; India fights disease in rural areas

UNICEF said that Myanmar is planning a mass polio vaccination campaign of children under age five after the country confirmed its first case of the disease in three years, Agence France-Presse reports.

24 Feb 2011

Novo Nordisk submits rFXIII BLA to FDA for treatment of inherited bleeding disorder

Novo Nordisk announced today that a Biologic License Application has been submitted to the U.S. Food and Drug Administration requesting the approval of a recombinant factor XIII compound for the vast majority of patients with congenital factor XIII deficiency, an inherited bleeding disorder.

From Novo Nordisk 23 Feb 2011

Researchers identify low-dose, two-drug cocktail that reduces noise-induced hearing loss in mice

Whether on a battlefield, in a factory or at a rock concert, noise-induced hearing loss is one of the most common hazards people face. Researchers at Washington University School of Medicine in St. Louis have identified a low-dose, two-drug cocktail that reduces hearing loss in mice when given before they are exposed to loud noise. The drugs, already FDA-approved for other conditions, also treat hearing loss after noise exposure.

23 Feb 2011

FDA grants Fast Track designation to Sunesis' vosaroxin for treatment of AML

Sunesis Pharmaceuticals, Inc. today announced that vosaroxin, the Company's lead drug candidate, has been granted Fast Track designation by the U.S. Food and Drug Administration for the potential treatment of relapsed or refractory acute myeloid leukemia in combination with cytarabine.

23 Feb 2011

Multi-national consortium develops new approaches to cure the flu

Pharmacelsus GmbH announces its participation in the 4 year multi-national research cooperation project “FLUCURE” supported by the European Union with the goal of developing novel, small molecule based therapeutics for respiratory diseases caused by influenza viruses. The consortium also joined Vironova AB and Beactica AB (Sweden), Pike Pharma GmbH (Switzerland) and university-based research groups from Italy, Germany, Bulgaria, Lithuania, and the Netherlands.

23 Feb 2011

Study results of NanoViricides anti-dengue drug candidates presented at NIH/NIAID sponsored conference

NanoViricides, Inc.announced today that Anil R. Diwan, PhD, President of the Company, gave a presentation on Friday, February 18th, that discussed the Company's anti-viral technology and more specifically, results from both in-vitro and in-vivo studies of its drug candidates against dengue virus infections that can potentially cause a fatal manifestation, viz. dengue hemorrhagic fever.

23 Feb 2011

Pharmacelsus participates in FLUCURE project to develop novel therapeutics against influenza

Pharmacelsus GmbH announces its participation in the 4 year multi-national research cooperation project "FLUCURE" supported by the European Union with the goal of developing novel, small molecule based therapeutics for respiratory diseases caused by influenza viruses.

23 Feb 2011

Healthcare professionals need evidence-based education, guidance about CAM use in maternity care

Complementary and alternative medicine is increasingly popular in maternity care, but healthcare professionals need formal evidence-based education and guidance about its use, according to a review in the March issue of the Journal of Advanced Nursing.

23 Feb 2011

USPTO issues patent to Synergy's SP-333 for treatment of IBD

Synergy Pharmaceuticals, Inc., a developer of new drugs to treat gastrointestinal disorders and diseases, announced today that on February 1, 2011 the U.S. Patent and Trademark Office issued U.S. Patent No. 7,879,802, covering Synergy's novel drug candidate SP-333 to treat inflammatory bowel disease.

23 Feb 2011

Survey: 67% of pharma and biotech companies outsource more than half of all clinical trials

Driving clinical development and speeding time to market through effective relationship management will be two of the key themes discussed at Pharma IQ's 2nd Annual Global Clinical Outsourcing Forum this May.

23 Feb 2011

Omeros announces license agreement with Daiichi Sankyo for PDE7 inhibitors

Omeros Corporation today announced that its exclusive license to phosphodiesterase 7 inhibitors from Daiichi Sankyo Co., Ltd. has been amended to include addiction and compulsive disorders in the field of use.

23 Feb 2011

Pharmaceutical News

Takeda submits NDA to FDA for fixed-dose combination of azilsartan medoxomil plus CLD to treat hypertension

G-CSF treatment improves inadequate endometrium during IVF cycles

New strategies to improve developing countries' access to low-cost generic drugs needed, experts say

UBC study shows Canadians and Americans receive different drug information online

Scientists find bovine colostrum can massively reduce leaky gut syndrome

Aminothiazoles as therapeutic leads for prion diseases

New vaccine offers hope against Hepatitis C

FDA approves ONGLYZA to treat type 2 diabetes patients with renal impairment

CST, Astellas Pharma enter commercialization partnership for cancer diagnostic, therapeutic products

Polio: Myanmar plans vaccination campaign after confirming first new case in three years; India fights disease in rural areas

Novo Nordisk submits rFXIII BLA to FDA for treatment of inherited bleeding disorder

Researchers identify low-dose, two-drug cocktail that reduces noise-induced hearing loss in mice

FDA grants Fast Track designation to Sunesis' vosaroxin for treatment of AML

Multi-national consortium develops new approaches to cure the flu

Study results of NanoViricides anti-dengue drug candidates presented at NIH/NIAID sponsored conference

Pharmacelsus participates in FLUCURE project to develop novel therapeutics against influenza

Healthcare professionals need evidence-based education, guidance about CAM use in maternity care

USPTO issues patent to Synergy's SP-333 for treatment of IBD

Survey: 67% of pharma and biotech companies outsource more than half of all clinical trials

Omeros announces license agreement with Daiichi Sankyo for PDE7 inhibitors

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News